INHERIT EGFR study expands to second site
SAN CARLOS, Calif., Oct. 30, 2013 /PRNewswire-USNewswire/ -- A new research
study, funded by the Bonnie J. Addario Lung Cancer Foundation (ALCF), is aiming
to understand how an inherited gene in some lung cancer patients could serve as
an early detection screening for family members.
"We're hoping this study provides new insight for methods to screen for lung
cancer in people who might not have otherwise qualified for screening: the
family members of lung cancer patients," said Bonnie J. Addario, lung cancer
survivor and founder of the ALCF. "And we also hope to show that lung cancer
doesn't just affect people who smoke."
The INHERIT (Investigating Hereditary Risk from T790M) research study,
facilitated by the Addario Lung Cancer Medical Institute (ALCMI), is the first
to apply inherited familial genetics - widely used to assess risk for breast and
colon cancer - to provide insight into lung cancer. Dr. Geoffrey Oxnard and a
team of physicians at Dana-Farber/Brigham and Women's Cancer Center in Boston,
MA are leading the INHERIT study to understand whether the presence of the T790M
gene mutation in lung cancers is associated with an inherited gene alteration.
Oxnard's team will also examine whether having the inherited form of T790M
raises the risk of lung cancer in patients and families. The ALCMI study was
launched at Dana-Farber and has now expanded to include Vanderbilt-Ingram Cancer
Center in Nashville, Tenn. No travel is required to participate.
"This is the first time we are using cancer genetics to offer insight into
inherited familial genetics. For breast cancer or colon cancer, it is patients
with a family history that get evaluated for inherited mutations in cancer risk
genes," said Geoffrey Oxnard, MD, the lead researcher on the study. "For lung
cancer, we propose that it is patients with specific genetic subtypes of lung
cancer, those carrying the EGFR T790M mutation, that need to be evaluated for an
inherited mutation in their family."
Ultimately, the study aims to identify individuals and families who may have an
increased risk of developing lung cancer so they can work with their physicians
to reduce and manage that risk. Understanding lung cancer's underlying biology
in high-risk families could also provide unique insight into why the disease
develops and determine whether "germline" (inherited) factors may partly explain
lung cancer in individuals without apparent carcinogenic association.
"We are funding this study because of our patient first commitment," Addario
said, "and with the hope to raise awareness that the risk for lung cancer exists
regardless of smoking history. In 2013 alone, 34,000 people who never smoked
will be diagnosed with lung cancer. That population of cancer patients,
isolated, would represent the seventh leading cancer in the U.S."
The INHERIT study is offered through Dana-Farber/Harvard Cancer Center,
Vanderbilt-Ingram Cancer Center, and soon at other ALCMI member institutions in
the United States and Europe. It is led by Geoffrey Oxnard, MD at
Dana-Farber/Brigham and Women's Cancer Center. Dana-Farber and Vanderbilt are
National Cancer Institute-designated Comprehensive Cancer Centers.
This study is also funded by the Conquer Cancer Foundation of the American
Society of Clinical Oncology (ASCO).
FOR MORE INFORMATION:
View video on T790 mutation research at www.dana-farber.org/T790Mstudy
Contact Dr. Oxnard at 617-632-6049, dfcifamilialT790M@dfci.harvard.edu
About the Bonnie J. Addario Lung Cancer Foundation
The Bonnie J. Addario Lung Cancer Foundation (ALCF) is one of the largest
philanthropies (patient-founded, patient-focused, and patient-driven) devoted
exclusively to eradicating Lung Cancer through research, early detection,
education, and treatment. The Foundation works with a diverse group of
physicians, organizations, industry partners, individuals, survivors, and their
families to identify solutions and make timely and meaningful change. The ALCF
was established on March 1, 2006 as a 501c(3) non-profit organization and has
raised more than $10 million for lung cancer research and patient services.
About the Addario Lung Cancer Medical Institute
The Addario Lung Cancer Medical Institute (ALCMI) is a patient-founded,
patient-focused 501c(3) non-profit research consortium established in 2008 that
directly facilitates basic and clinical research to accelerate the discovery and
delivery of advancements to patients. By bringing together a world-class team of
scientists and clinicians from over 20 academic and community medical centers in
the U.S. and Europe, ALCMI has rapidly established a critical mass of expertise
and dedicated research infrastructures linked together through centrally
SOURCE Bonnie J. Addario Lung Cancer Foundation